Navigation Links
Parents report a widely prescribed antibiotic is effective for fragile X treatment
Date:9/8/2010

(SACRAMENTO, Calif.) One of the antibiotics most commonly prescribed to treat adolescent acne can increase attention spans and communication and decrease anxiety in patients with fragile X syndrome, the most common inherited cause of mental impairment, according to a new survey study that is the first published on parents' reports of their children's responses to treatment with the medication.

Led by researchers at the UC Davis MIND Institute, the study examined parents' observations of their children's responses to minocycline not the efficacy of treating patients with the drug. However, the researchers said that the study results are extremely promising. They led to a placebo-controlled clinical trial of treating people with fragile X with minocycline, funded by the National Fragile X Foundation.

"Minocycline Treatment in Patients with Fragile X Syndrome and Exploration of Outcome Measures" is published in the September 2010 issue of the American Journal of Intellectual and Developmental Disabilities. In the study, parents relate that after being treated for an average of three months, their children showed improvements in their use of language, attention levels and behavior, while experiencing mostly mild side effects.

"This preliminary survey demonstrated improvements in participants, however, a controlled clinical trial is needed to compare the efficacy of treating patients with minocycline to treatment with a placebo," said Randi Hagerman, Fragile X Endowed Chair, medical director of the UC Davis MIND Institute and one of the world's leading experts on fragile X syndrome.

Fragile X syndrome is a genetic disorder, the result of a defect on the X chromosome. It is estimated to affect 1 in 3,600 males and 1 in 4,000 females. One-third of all children with fragile X syndrome develop autism and approximately 5 percent of children with an autism-spectrum disorder have fragile X.

The condition causes a range of disabilities, from learning disorders to mild-to-severe intellectual impairment (mental retardation) and behavioral and emotional problems. It also is associated with certain physical characteristics, including prominent ears and flexible finger joints. The symptoms typically are more severe in boys than in girls.

Minocycline is one of the most commonly prescribed medications for adolescent acne and has been in use since its introduction in the 1960s. The drug also has been found to have neuroprotective qualities and in animal models improves neurodegenerative diseases like Parkinson's and Huntington's. Interest in its use in human patients with fragile X surged after a 2009 study found that minocycline improved cognition in mice genetically engineered to have fragile X. That study's senior author was Iryna M. Ethell of UC Riverside, who also is an author with Hagerman of the current research.

Ethell and her colleagues in 2009 found that minocycline lowers the levels of matrix metalloproteinase 9 (MMP9), an enzyme present in the normal brain whose levels and activity are over-expressed in the fragile X mouse. MMP9 inhibits development of structures called dendritic spines, tiny mushroom-like projections at the ends of synapses that allow neural cells to communicate. Lowering the amount and activity of MMP9 strengthens the dendritic spines and improves the establishment and maintenance of circuits in the brain.

"It's really exciting to see applications like this of our mouse-model research," Ethell said.

For the parent study, Hagerman prescribed minocycline to patients at the Fragile X Research and Treatment Center at the MIND Institute. Other participants were treated elsewhere by their primary-care physicians. The study included a total of 53 patients, three of whom dropped out after a few days because of side effects. The remaining 50 participants, seven females and 43 males, took the drug for between two weeks and 20 months, with dosages of 25 to 200 milligrams per day. Participants ranged in age from 4 months to 25 years.

Fifty-four percent of the participants' parents said their children showed improvements in their use of language. Fifty percent said their children's attention spans improved. Forty-four percent said their children's social communication improved and 30 percent said their children's anxiety levels decreased. Most said their children experienced mild side effects, such as an upset stomach. Hagerman had wanted to learn whether the patients would experience the tooth discoloration common to individuals using tetracyclines. Reports of those side effects were minimal.

In anecdotal reports, parents said that after taking minocycline their children used more language, had clearer speech and were more understandable. Some said their children were "becoming more conversational, articulate and talkative," the study states. Parents also reported that their children were more focused and "had longer attention spans when playing, doing homework or participating in another activity."

The study findings prompted the National Fragile X Foundation to fund a two-year, $100,000 pilot study of the use of minocycline in people with fragile X. The study is examining the efficacy of using the antibiotic to treat children between the ages of 4 and 16.

"The National Fragile X Foundation is honored to be able to support a research project that has the potential to bring significant improvement, in a relatively short period of time, to individuals with fragile X syndrome," said Executive Director Robert Miller. "We know that families also are excited about this possibility. A goal of the National Fragile X Foundation is to move research forward that translates scientific breakthroughs into near-term treatments and this study has the potential to do just that."

The study was conducted in collaboration with lead author Agustini Utari, a fellow at the UC Davis MIND Institute from the Center for Biomedical Research, Diponegoro University, Indonesia, where the prevalence of fragile X syndrome appears to be high. Utari has returned to Indonesia, where she plans to conduct a minocycline study.

"I am very excited about the opportunity to bring a study of minocycline and fragile X to Indonesia," Utari said.


'/>"/>

Contact: Phyllis Brown
phyllis.brown@ucdmc.ucdavis.edu
916-734-9023
University of California - Davis - Health System
Source:Eurekalert

Related medicine news :

1. Explorers Bounty Puffed Fruit Snacks Helping Parents Battle Summer Obesity
2. Parents often wait too long to treat childrens asthma symptoms
3. New intervention helps Latino parents of asthmatic children quit smoking
4. PDA Reminds Parents About the Importance of Childrens Oral Health
5. New Virtual Program for Parents of Children with ADD / ADHD
6. Parents Divorce Doesnt Harm College-Age Kids
7. Some Parents Consider Hastening a Sick Childs Death
8. Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children
9. Mother of Binge Drinking Victim Urges Students and Parents to Discuss Signs of Alcohol Poisoning, Emphasize Peer Responsibility Prior to Spring Break
10. Twinlab Launches New Omega-3 Powder in Single-Serving Stick Packs for Busy Parents and Their Kids
11. Risks of Kids Surgeries May Not Stick With Parents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... training, today announced the launch of a new research study, The Business Readiness ... needed to execute that strategy, and the actual success of achieving individual and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Janet Schloz is still in shock after receiving ... days I’ve had in a long time,” she said. , She thinks the coming week ... that I never thought I would have to help my students.” , The award will ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. ... launch of a months-long rebranding effort. This includes the introduction of new packaging ... discussions and market research, we learned that a simple, proactive approach to wellness ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion ... renovations is also on the rise. Per a 2017 report, 13% of all households ... to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only ...
(Date:3/25/2017)... ... , ... Norland at Swissray is pleased to announce the release of the ELITE ... DXA has an active scan window, which is more than double that of existing bone ... area could not undergo an accurate total body bone density or body composition study. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... The global wound care market was worth $24,482.9 ... of 6.7% during 2016-2022 Among the various wound care products ... the global market in 2015. Among the various applications, surgical wound segment ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the ... Inc., projects that the global medical cannabis market will reach a value ... is a major market for the new growing industry. By the end ... legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology: